Nothing Special   »   [go: up one dir, main page]

MA38930A1 - Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r) - Google Patents

Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)

Info

Publication number
MA38930A1
MA38930A1 MA38930A MA38930A MA38930A1 MA 38930 A1 MA38930 A1 MA 38930A1 MA 38930 A MA38930 A MA 38930A MA 38930 A MA38930 A MA 38930A MA 38930 A1 MA38930 A1 MA 38930A1
Authority
MA
Morocco
Prior art keywords
antibody
csf1r
stimulating factor
colony stimulating
receptor
Prior art date
Application number
MA38930A
Other languages
English (en)
Inventor
Graham Craggs
Karine Jeannine Madeleine Herve
Diane Marshall
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38930(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA38930A1 publication Critical patent/MA38930A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne un anticorps anti-csf-1r et des fragments de liaison associés, de l'adn codant pour celui-ci, des cellules hôtes comportant ledit adn et des méthodes d'expression de l'anticorps ou d'un fragment de liaison dans une cellule hôte. La présente invention s'étend également à des compositions pharmaceutiques comprenant l'anticorps ou un fragment de liaison associé, et l'utilisation de l'anticorps, du fragment de liaison et des compositions les comprenant dans un traitement.
MA38930A 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r) MA38930A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315487.7A GB201315487D0 (en) 2013-08-30 2013-08-30 Antibodies
PCT/EP2014/068050 WO2015028455A1 (fr) 2013-08-30 2014-08-26 Anticorps

Publications (1)

Publication Number Publication Date
MA38930A1 true MA38930A1 (fr) 2017-12-29

Family

ID=49397073

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44922A MA44922B1 (fr) 2013-08-30 2014-08-26 Anticorps
MA38930A MA38930A1 (fr) 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA44922A MA44922B1 (fr) 2013-08-30 2014-08-26 Anticorps

Country Status (39)

Country Link
US (2) US9908939B2 (fr)
EP (3) EP3549599B1 (fr)
JP (3) JP6632075B2 (fr)
KR (1) KR102303130B1 (fr)
CN (2) CN105658236B (fr)
AR (1) AR097464A1 (fr)
AU (1) AU2014314304B2 (fr)
BR (1) BR112016004324B1 (fr)
CA (1) CA2922240C (fr)
CL (1) CL2016000438A1 (fr)
CY (1) CY1121964T1 (fr)
DK (2) DK3038643T3 (fr)
EA (1) EA036255B1 (fr)
ES (2) ES2965207T3 (fr)
FI (1) FI3549599T3 (fr)
GB (1) GB201315487D0 (fr)
HK (1) HK1220142A1 (fr)
HR (2) HRP20231264T1 (fr)
HU (2) HUE064437T2 (fr)
IL (1) IL244043B (fr)
LT (2) LT3038643T (fr)
MA (2) MA44922B1 (fr)
MX (1) MX2016002166A (fr)
MY (1) MY172484A (fr)
NZ (1) NZ717399A (fr)
PE (2) PE20160528A1 (fr)
PH (1) PH12016500275A1 (fr)
PL (2) PL3038643T3 (fr)
PT (2) PT3549599T (fr)
RS (2) RS59019B1 (fr)
SG (1) SG11201601151PA (fr)
SI (2) SI3038643T1 (fr)
TN (1) TN2016000067A1 (fr)
TR (1) TR201909478T4 (fr)
TW (1) TWI531582B (fr)
UA (1) UA118354C2 (fr)
UY (1) UY35718A (fr)
WO (1) WO2015028455A1 (fr)
ZA (1) ZA201601437B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
MY195000A (en) 2015-05-27 2022-12-30 Ucb Biopharma Sprl Method for the treatment of neurological disease
WO2016196679A1 (fr) * 2015-06-02 2016-12-08 Genentech, Inc. Compositions et méthodes d'utilisation d'anticorps anti-il -34 pour traiter des maladies neurologiques
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
WO2018183366A1 (fr) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Polythérapies d'anticorps csf-1r ou csf-1 et thérapie reposant sur des lymphocytes t
KR102651568B1 (ko) * 2017-05-19 2024-03-25 신닥스 파마슈티컬스, 인크. 조합 요법
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN108948198B (zh) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其应用
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
TWI733274B (zh) 2018-12-13 2021-07-11 財團法人生物技術開發中心 抗人類csf-1r抗體及其用途
CN113939539B (zh) * 2019-05-15 2024-06-04 博奥信生物技术（南京）有限公司 结合csf-1r的抗体及其用途
WO2021119128A1 (fr) * 2019-12-09 2021-06-17 Syndax Pharmaceuticals, Inc. Anticorps pour le traitement d'une maladie chronique du greffon contre l'hôte
EP4081255A4 (fr) * 2019-12-24 2024-04-03 Adagene (Suzhou) Limited Molécules anti-csf1r et utilisation correspondante

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1644412T2 (sl) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modificirani fab fragmenti protiteles
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
JP5805393B2 (ja) 2008-03-14 2015-11-04 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． Ｃｓｆ−１ｒに対する抗体
US8470977B2 (en) * 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2010035012A1 (fr) 2008-09-26 2010-04-01 Ucb Pharma S.A. Produits biologiques
EP2475682B1 (fr) 2009-09-10 2018-01-31 UCB Biopharma SPRL Anticorps multivalents
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
BR112012013717B1 (pt) * 2009-12-10 2020-01-28 Hoffmann La Roche anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CN102918060B (zh) 2010-03-05 2016-04-06 霍夫曼-拉罗奇有限公司 抗人csf-1r抗体及其用途
JP5989547B2 (ja) * 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
AU2011248083B2 (en) 2010-05-04 2015-09-10 Five Prime Therapeutics, Inc. Antibodies that bind CSF1R
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
KR102303130B1 (ko) 2021-09-16
RS64784B1 (sr) 2023-11-30
UY35718A (es) 2015-03-27
US10421814B2 (en) 2019-09-24
ES2965207T3 (es) 2024-04-11
SI3038643T1 (sl) 2019-08-30
RS59019B1 (sr) 2019-08-30
MA44922A1 (fr) 2019-08-30
JP2022002523A (ja) 2022-01-11
MX2016002166A (es) 2016-06-23
PE20160528A1 (es) 2016-05-21
EP3038643B1 (fr) 2019-05-01
JP6632075B2 (ja) 2020-01-15
TR201909478T4 (tr) 2019-07-22
CN105658236B (zh) 2021-03-19
CN105658236A (zh) 2016-06-08
BR112016004324A2 (pt) 2017-10-24
UA118354C2 (uk) 2019-01-10
TN2016000067A1 (en) 2017-07-05
US20160200821A1 (en) 2016-07-14
PT3549599T (pt) 2023-11-21
ES2733735T3 (es) 2019-12-02
EP3038643A1 (fr) 2016-07-06
PT3038643T (pt) 2019-07-25
AU2014314304B2 (en) 2019-12-05
DK3549599T5 (da) 2024-09-02
US20180162947A1 (en) 2018-06-14
HUE045672T2 (hu) 2020-01-28
WO2015028455A1 (fr) 2015-03-05
SI3549599T1 (sl) 2023-12-29
EP4282881A3 (fr) 2024-02-21
EP3549599A1 (fr) 2019-10-09
ZA201601437B (en) 2018-08-29
GB201315487D0 (en) 2013-10-16
EA036255B1 (ru) 2020-10-20
CA2922240C (fr) 2023-09-05
PE20201067A1 (es) 2020-10-19
PH12016500275B1 (en) 2016-05-02
FI3549599T3 (fi) 2023-10-31
KR20160044018A (ko) 2016-04-22
PL3549599T3 (pl) 2024-03-04
NZ717399A (en) 2021-12-24
IL244043A0 (en) 2016-04-21
PH12016500275A1 (en) 2016-05-02
DK3549599T3 (en) 2023-10-30
MA44922B1 (fr) 2020-06-30
CL2016000438A1 (es) 2016-11-11
AU2014314304A1 (en) 2016-03-17
JP2016529266A (ja) 2016-09-23
BR112016004324B1 (pt) 2024-01-16
CY1121964T1 (el) 2020-10-14
SG11201601151PA (en) 2016-03-30
EA201690503A1 (ru) 2016-06-30
TWI531582B (zh) 2016-05-01
JP2020005652A (ja) 2020-01-16
HK1220142A1 (zh) 2017-04-28
JP7195237B2 (ja) 2022-12-23
US9908939B2 (en) 2018-03-06
EP3549599B1 (fr) 2023-09-06
HRP20191051T1 (hr) 2019-09-06
HUE064437T2 (hu) 2024-03-28
EP4282881A2 (fr) 2023-11-29
AR097464A1 (es) 2016-03-16
CN112321711A (zh) 2021-02-05
CN112321711B (zh) 2024-11-08
MY172484A (en) 2019-11-26
PL3038643T3 (pl) 2019-11-29
HRP20231264T1 (hr) 2024-02-02
CA2922240A1 (fr) 2015-03-05
LT3038643T (lt) 2019-07-25
DK3038643T3 (da) 2019-06-24
TW201512221A (zh) 2015-04-01
IL244043B (en) 2021-01-31
LT3549599T (lt) 2023-11-10

Similar Documents

Publication Publication Date Title
MA38930A1 (fr) Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
MA32948B1 (fr) Anticorps anti-pd-l1 et leur utilisation pour ameliorer la fonction des lymphocytes t
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
ZA201604468B (en) Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
EA201400625A1 (ru) Антитела против pd-l1 и их применение
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
MA39096B1 (fr) Anticorps spécifiques à fcrn
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
WO2014031646A3 (fr) Molécules présentant une activité de liaison à l'antigène et de liaison aux récepteurs polyvalents fc gamma
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
UA104663C2 (en) Antibody binding to cd127
MA38860B1 (fr) Cellule progénitrice immuno-modulatrice (imp)
IN2014CN04645A (fr)
EA201591762A1 (ru) Человеческие антитела к grem1
EA201590247A1 (ru) Антитела к siglec-15
MA38190A2 (fr) Inhibiteurs d'autotaxine
EA201290759A1 (ru) Антитела
MA39342B2 (fr) Anticorps il -21
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201891612A1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
EA201891610A1 (ru) Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана